Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Shien Guo, PhD, Weiqin Liao, MS, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2207.

https://doi.org/10.1182/blood-2019-129386

Published: 2019

Journal Articles

Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms

Ken-Hong Lim, MD, Yu-Cheng Chang, MD, Yi-Hao Chiang, MD, Huan-Chau Lin, MD, Ling Huang, MSc, Wei-Ting Wang, MSc, Ying-Wen Su, MD, PhD, Ming-Chih Chang, MD, Yi-Fang Chang, MD PhD, Caleb Gon-Shen Chen, MD PhD

Blood (2019) 134 (Supplement_1): 2970.

https://doi.org/10.1182/blood-2019-124420

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, MD PhD, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Jun Zhang, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 668.

https://doi.org/10.1182/blood-2019-129288

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Ruben A Mesa, MD, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Carrie Brownstein, MD, Shien Guo, PhD, Xiaomei Ye, MS, Claire N Harrison, Professor

Blood (2019) 134 (Supplement_1): 704.

https://doi.org/10.1182/blood-2019-129020

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Juan Shen, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 4165.

https://doi.org/10.1182/blood-2019-130069

Published: 2019

Journal Articles

Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients

Blood (2018) 132 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2018-99-115318

Published: 2018

Journal Articles

Myelofibrosis Drug Development through the Decade: Novel JAK Inhibitors

Ali Younas Khan, MD, Muhammad Junaid Tariq, MD, Muhammad Usman, MD, Awais Ijaz, MD, Abdul Rafae, MD, Mustafa Nadeem Malik, MD, Hafiz Muhammad Fazeel, MD, Nadia Carenina Nunes Cavalcante Parr, MD, Muhammad Asad Fraz, MD, Muhammad Jahanzeb Khalil, MD, Jemin Aby Jose, MD, Seren Durer, MD, Ceren Durer, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5477.

https://doi.org/10.1182/blood-2018-99-115408

Published: 2018

Journal Articles

Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients

Blood (2018) 132 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2018-99-116289

Published: 2018

Journal Articles

The role of JAK2 inhibitors in MPNs 7 years after approval

Francesco Passamonti, Margherita Maffioli

Blood (2018) 131 (22): 2426–2435.

https://doi.org/10.1182/blood-2018-01-791491

Published: 2018

Journal Articles

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

Blood (2017) 130 (Supplement 1): 1643.

https://doi.org/10.1182/blood.V130.Suppl_1.1643.1643

Published: 2017

Journal Articles

Case Series of Potential Wernicke's Encephalopathy in Patients Treated with Fedratinib

Claire N. Harrison, BMBCh, DM, FRCP, FRCPath, Ruben A Mesa, MD, Catriona Jamieson, MD PhD, John Hood, PhD, Julie Bykowski, MD, Giulio Zuccoli, MD, James Brewer, MD,PhD

Blood (2017) 130 (Supplement 1): 4197.

https://doi.org/10.1182/blood.V130.Suppl_1.4197.4197

Published: 2017

Journal Articles

Fedratinib Does Not Inhibit Thiamine Uptake or Induce Experimental Wernicke's Encephalopathy in Nonclinical Studies

John Hood, PhD, Alan Hazell, PhD

Blood (2017) 130 (Supplement 1): 4993.

https://doi.org/10.1182/blood.V130.Suppl_1.4993.4993

Published: 2017

Journal Articles

Potential Therapeutic Applications of Jak2 Inhibitors and Hif2a-ASO for the Treatment of β-Thalassemia Intermedia and Major

Carla Casu, Paraskevi Rea Oikonomidou, MD, Vania Lo Presti, Mariam Aghajan, PhD, Shuling Guo, PhD, Abdulmalik Osheiza, Luca Melchiori, Pedro Ramos, Stefano Rivella, PhD

Blood (2016) 128 (22): 1012.

https://doi.org/10.1182/blood.V128.22.1012.1012

Published: 2016

Journal Articles

Inhibition of JAK2/STAT3 Pathway Leads to Apoptosis in Chronic Lymphocytic Leukemia Cells

Filippo Severin, PhD, Federica Frezzato, PhD, Veronica Martini, PhD, Flavia Raggi, MS, Valentina Trimarco, PhD, Leonardo Martinello, MS, Andrea Visentin, MD, Monica Facco, MS, Gianpietro Semenzato, MD, Livio Trentin, MD

Blood (2016) 128 (22): 2023.

https://doi.org/10.1182/blood.V128.22.2023.2023

Published: 2016

Journal Articles

Chemical Mutagenesis Screen Identifies Novel Drug Resistant JAK2 Variants in V617FJAK2 Mediated MPN and Predict HSP90 Inhibitors As Possible Agents to Overcome Drug Resistance

Sivahari Prasad Gorantla, PhD, Detlef Bentrop, PhD, Nikolas Bubnoff, MD, Anna Lena Illert, MD, Robert Zeiser, MD, Justus Duyster, MD

Blood (2015) 126 (23): 3687.

https://doi.org/10.1182/blood.V126.23.3687.3687

Published: 2015

Journal Articles

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Francesca Gesullo, BS, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Carmela Mannarelli, MSc, Giuseppe Loscocco, Chiara Paoli, BS, Lucia Merli, BSN, Alessandro M. Vannucchi

Blood (2015) 126 (23): 353.

https://doi.org/10.1182/blood.V126.23.353.353

Published: 2015

Journal Articles

Inflammatory Cytokine-Responsive ADAR1 Impairs Let-7 Biogenesis and Promotes Leukemia Stem Cell Generation

Maria Anna Zipeto, PhD, Angela Court Recart, Nathaniel Delos Santos, Qingfei Jiang, PhD, Leslie A Crews, PhD, Catriona HM Jamieson, MD PhD

Blood (2015) 126 (23): 4014.

https://doi.org/10.1182/blood.V126.23.4014.4014

Published: 2015

Journal Articles

The JAK1/2 Inhibitor Momelotinib Does Not Inhibit Thiamine Uptake in Vitro

Marilyn Giacomini, Jia Hao, Xiaomin Liang, Jayaraman Chandrasekhar, Jolyn Twelves, Andy Whitney, Irene Lepist, Adrian Ray

Blood (2015) 126 (23): 4099.

https://doi.org/10.1182/blood.V126.23.4099.4099

Published: 2015

Journal Articles

IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers

Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Elisa Rumi, MD, Paola Guglielmelli, MD PhD, Rajmonda Fjerza, MD, Chiara Paoli, BS, Lucia Merli, BSN, Mario Cazzola, MD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1615.

https://doi.org/10.1182/blood.V126.23.1615.1615

Published: 2015

Journal Articles

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Sara C Meyer, MD PhD, Matthew D Keller, BS, Priya Koppikar, PhD, Olga A Guryanova, MD PhD, Maria Kleppe, PhD, Anna Sophia McKenney, MPH, William R Sellers, MD, Francesco Hofmann, PhD, Fabienne Baffert, Christoph Gaul, PhD, Thomas Radimerski, PhD, Ross L Levine, MD

Blood (2014) 124 (21): 160.

https://doi.org/10.1182/blood.V124.21.160.160

Published: 2014

NARROW

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients

Myelofibrosis Drug Development through the Decade: Novel JAK Inhibitors

Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients

The role of JAK2 inhibitors in MPNs 7 years after approval

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

Case Series of Potential Wernicke's Encephalopathy in Patients Treated with Fedratinib

Fedratinib Does Not Inhibit Thiamine Uptake or Induce Experimental Wernicke's Encephalopathy in Nonclinical Studies

Potential Therapeutic Applications of Jak2 Inhibitors and Hif2a-ASO for the Treatment of β-Thalassemia Intermedia and Major

Inhibition of JAK2/STAT3 Pathway Leads to Apoptosis in Chronic Lymphocytic Leukemia Cells

Chemical Mutagenesis Screen Identifies Novel Drug Resistant JAK2 Variants in V617FJAK2 Mediated MPN and Predict HSP90 Inhibitors As Possible Agents to Overcome Drug Resistance

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Inflammatory Cytokine-Responsive ADAR1 Impairs Let-7 Biogenesis and Promotes Leukemia Stem Cell Generation

The JAK1/2 Inhibitor Momelotinib Does Not Inhibit Thiamine Uptake in Vitro

IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only